Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer

BACKGROUND: Trifluridine/tipiracil (FTD/TPI) showed clinical benefit, including improved survival and manageable safety in previously treated patients with metastatic colorectal (mCRC) or gastric/gastroesophageal junction (mGC/GEJC) cancer in the phase III RECOURSE and TAGS trials, respectively. A p...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Cutsem, E., Hochster, H., Shitara, K., Mayer, R., Ohtsu, A., Falcone, A., Yoshino, T., Doi, T., Ilson, D.H., Arkenau, H.-T., George, B., Benhadji, K.A., Makris, L., Tabernero, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808443/
https://www.ncbi.nlm.nih.gov/pubmed/36455504
http://dx.doi.org/10.1016/j.esmoop.2022.100633

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808443/
https://www.ncbi.nlm.nih.gov/pubmed/36455504
http://dx.doi.org/10.1016/j.esmoop.2022.100633

Ejemplares similares